Apimeds Pharmaceuticals US (APUS) Current Assets (2023 - 2025)

Apimeds Pharmaceuticals US has reported Current Assets for 3 years, with the latest figure at $14.0 million in Q4 2025.

• For the quarter ending Q4 2025, Current Assets rose 106998.56% year-over-year to $14.0 million; the trailing twelve-month figure through Dec 2025 stood at $14.0 million (up 106998.56% YoY), and the FY2025 full-year result was $14.0 million, up 106998.56% from the prior year.
• Current Assets for Q4 2025 stood at $14.0 million, up from $9.1 million in the prior quarter.
• The five-year high for Current Assets was $14.0 million in Q4 2025, with the low at $13057.0 in Q4 2024.
• Historically, Current Assets has averaged $5.7 million across 3 years, with a median of $4.8 million in 2023.
• Annual changes were most pronounced in 2024 — Current Assets sank 96.91% — and 2025, when it soared 106998.56%.
• Apimeds Pharmaceuticals US's Current Assets stood at $422076.0 in 2023, then slumped by 96.91% to $13057.0 in 2024, then soared by 106998.56% to $14.0 million in 2025.
• The last three Current Assets figures came in at $14.0 million (Q4 2025), $9.1 million (Q3 2025), and $10.3 million (Q2 2025), per Business Quant data.